Key emerging themes for assessing the cost-effectiveness of reporting incidental findings
To the Editor: We congratulate Bennette et al. for an innovative first step to addressing a challenging issue-how to assess the cost-effectiveness of reporting incidental findings (IFs) discovered with sequencing technologies-as described in their article, "The Cost-Effectiveness of Returning Incidental Findings From NextGeneration Genomic Sequencing. "
1 At the University of California at San Francisco Center for Translational and Policy Research on Personalized Medicine, we are conducting related analyses that further inform these issues. 2 We would like to highlight key emerging themes and suggestions for future work and to discuss the importance of some assumptions made by Bennette et al. that could greatly impact the findings of cost-effectiveness analyses.
Of particular importance for future work is the need to examine the likely cost-effectiveness in real-world settings. Bennette et al. 1 assumed that individuals would remain at risk but not be detected through any other means during their lifetime (other than for familial hypercholesterolemia). However, particularly for the two most prevalent conditions they examined (hereditary breast and ovarian cancer; Lynch syndrome), many individuals with the conditions will be identified even if there is no sequencing. By assigning all benefits to the detection of IFs, the costeffectiveness of reporting IFs in real-world settings will seem better. We thus suggest that future analyses consider including a background rate of detection rather than using "nothing" as a comparator, which would enable the findings to be more comparable with those of other analyses that follow the standard approach of comparing an intervention to current practice. 3 Other simplifying assumptions that Bennette et al. 1 acknowledge could affect their results. First, aggregating results of different models is a reasonable first step, but it is unclear how sensitive the results are to the assumptions of individual models and whether it is reasonable to aggregate possibly heterogeneous findings-with different populations and modeling approaches-into an overall cost-effectiveness ratio. Many previous studies (e.g., Vegter et al. 4 ) have noted the heterogeneity found across cost-effectiveness analyses of genetic testing. In future research, it would be helpful to develop a transparent means of aggregating results so that they can be readily replicated. Second, future analyses could take into account interactive effects, namely, the differences in life-expectancy from finding one result when evaluating the potential effects of another result. The likelihood of finding more than one IF in a given person is very small in the current analysis but will increase as more returnable IFs are identified in the future. Third, in real clinical practice, it is possible that unproven and potentially costly management strategies could be used in a fraction of individuals receiving a given IF result. Not accounting for this may miss an important determinant of downstream clinical effectiveness and cost.
In sum, the approach of Bennette et al. 1 provides an important initial approach for analyses that can continue to refine approaches to defining and measuring the value of new genomic testing technologies that return multiple results. It should be noted that the results to date suggest that reporting IFs may be cost-effective in certain scenarios but are not generally 
To the Editor:
We thank Dr Phillips and colleagues for their interest in our work and for raising several important points in assessing the cost-effectiveness of reporting incidental findings from clinical sequencing. 1 We agree with the importance of comparing a novel intervention to current practice-indeed a key concept in cost-effectiveness analysis-and would like to clarify that we included a "baseline rate of detection" within our original modeling framework. 2 In other words, individuals who carry a mutation that is not returned as an incidental finding receive ongoing surveillance according to practice guidelines. It is because of this baseline rate of detection that the individual-level incremental health benefits associated with incidental findings for the more prevalent conditions (hereditary breast and ovarian cancer and Lynch syndrome) are relatively small, despite the availability of effective prophylactic interventions that could dramatically reduce an individual's risk.
Regarding heterogeneous findings from different models, we evaluated all relevant studies for each clinical condition and specifically noted heterogeneity in results, as well as how different assumptions or inputs in each study likely contributed to these differences. We also independently verified with several clinical genetics experts the key assumptions and modeling inputs of each study included in our policy model. Because of space limitations, this work is summarized in the article's Supplementary Methods and Materials online for interested readers.
The potential for interactive effects between incidental findings within our modeling framework is low based on the frequency of the diseases considered as incidental findings; we estimated ~0.01% chance for an otherwise healthy 45-year-old. We therefore decided that the considerable increase in model complexity to account for potential interactive effects was not worth the negligible expected difference in our results. We agree that if the number of potential incidental findings to be returned increases dramatically, this will be an important point to revisit.
Finally, it is possible that unproven and potentially costly management strategies could be used in a fraction of individuals who receive an incidental finding. It is also possible that individuals with an incidental finding will receive less treatment than expected based on recommended management strategies developed primarily for selected high-risk populations. We addressed this uncertainty in our model by assigning probabilistic distributions to these costs. However, there is a paucity of evidence about how individuals will respond to receiving incidental findings in terms of health-care utilization or other behaviors, which highlights the importance of ongoing research efforts such as the National Human Genome Research Institute-funded Clinical Sequencing Exploratory Research program. 3 We look forward to refining and updating our model in response to the evidence that emerges from this and other research.
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